EP3856252A1 — Solution comprising treosulfan
Assigned to Medac Gesellschaft fuer Klinische Spezialpraeparate mbH · Expires 2021-08-04 · 5y expired
What this patent protects
A solution is described which comprises treosulfan and a mixture of water and acetic acid and leads, upon freeze-drying, to a lyophilisate which possesses favourable characteristics in terms of a short reconstitution time and a high purity and stability and which is particularly …
USPTO Abstract
A solution is described which comprises treosulfan and a mixture of water and acetic acid and leads, upon freeze-drying, to a lyophilisate which possesses favourable characteristics in terms of a short reconstitution time and a high purity and stability and which is particularly useful in the treatment of cancer and for conditioning therapy before transplantation of bone marrow or blood stem cells.
Drugs covered by this patent
- Trecondi (TREOSULFAN) · Medexus
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.